Detalhe da pesquisa
1.
IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies.
Retina
; 43(4): 632-640, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36705252
2.
Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study.
Diabet Med
; 39(4): e14746, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34796985
3.
Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.
Ophthalmologica
; 245(4): 315-322, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35344964
4.
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration.
Ophthalmologica
; 244(2): 93-101, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33197916
5.
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
COPD
; 15(2): 185-191, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658810
6.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Circulation
; 134(8): 589-98, 2016 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27496855
7.
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Respir Res
; 18(1): 140, 2017 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28720132
8.
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
Respir Res
; 18(1): 13, 2017 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28077140
9.
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.
Eur Respir J
; 48(5): 1369-1376, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27471209
10.
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
Europace
; 18(7): 973-8, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26944733
11.
Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting.
Thromb J
; 14: 8, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27042163
12.
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
Value Health
; 18(2): 234-49, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25773559
13.
Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery.
Thromb J
; 13: 37, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26612979
14.
Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials.
Thromb J
; 13: 36, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26578849
15.
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Am Heart J
; 167(3): 329-34, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24576516
16.
Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.
Anesthesiology
; 120(6): 1429-40, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24714118
17.
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.
Europace
; 15(11): 1540-56, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23981824
18.
Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Acta Ophthalmol
; 101(2): 123-139, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117281
19.
Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study.
Br J Ophthalmol
; 107(1): 96-101, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34362776
20.
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.
Sci Transl Med
; 15(681): eabq5241, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724238